Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
9,75 USD | -7,50% | -9,81% | +26,95% |
09/04 | Astria Therapeutics, Inc. benoemt Sunil Agarwal in zijn raad van bestuur | CI |
26/03 | ASTRIA THERAPEUTICS, INC. : Wedbush handhaaft koopadvies | ZM |
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 535 mln. 503 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -79 mln. -74,16 mln. | Nettowinst (verlies) 2025 * | -101 mln. -94,81 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-6,3
x | K/w-verhouding 2025 * |
-4,95
x | Werknemers | 59 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 87,7% |
Recentste transcriptie over Astria Therapeutics, Inc.
1 dag | -7,50% | ||
1 week | -9,81% | ||
Lopende maand | -30,73% | ||
1 maand | -41,58% | ||
3 maanden | +26,13% | ||
6 maanden | +87,50% | ||
Lopend jaar | +26,95% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Jill Milne
FOU | Founder | 56 | 26-06-08 |
Noah Clauser
DFI | Director of Finance/CFO | 51 | 01-04-11 |
Chief Tech/Sci/R&D Officer | - | 15-07-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Ken Bate
CHM | Chairman | 73 | 01-01-14 |
Gregg Lapointe
BRD | Director/Board Member | 65 | 04-01-19 |
Director/Board Member | 75 | 05-04-16 |
Naam | Gewicht | Volume | Vaira. 1 jan. | belegger rating |
---|---|---|---|---|
0.03% | 2 M€ | -.--% | ||
0.00% | 34 M€ | +1,25% | - |
Datum | Koers | Variatie | Volume |
---|---|---|---|
19-04-24 | 9,75 | -7,50% | 1 243 180 |
18-04-24 | 10,54 | -0,09% | 319 177 |
17-04-24 | 10,55 | -4,95% | 553 588 |
16-04-24 | 11,1 | +1,93% | 461 230 |
15-04-24 | 10,89 | +0,74% | 469 038 |
uitgestelde koers Nasdaq, 19 april 2024 om 22:00 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+26,95% | 579 mln. | |
-3,10% | 102 mld. | |
+2,11% | 96,07 mld. | |
-1,80% | 21,66 mld. | |
-17,75% | 20,77 mld. | |
-6,91% | 18,53 mld. | |
-42,00% | 16,91 mld. | |
-28,19% | 13,79 mld. | |
+0,18% | 13,33 mld. | |
+19,90% | 10,94 mld. |